--Guidance for cash usage in 2H08 is $14M (excluding any financing transactions or new partnership deals).
--3Q08 will benefit from the initial $3M payment from Ovation (provided that the deal actually closes).
--4Q08 will benefit from the next $2M payment from Ovation, assuming that the FDA accepts the ATryn BLA for review during the quarter.
--3Q08/4Q08 will benefit from a $3M reimbursement by LFB for the companies’ joint venture. (This is in addition to the $3M reimbursement from LFB during 2Q08.)
Let’s talk biotech! “If your beloved drug candidate sounds too good to be true, it probably is.”
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”